This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BRAF V600E Mutations In Papillary Thyroid Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by Bezmialem Vakif University.
Recruitment status was:  Recruiting
Information provided by:
Bezmialem Vakif University Identifier:
First received: July 6, 2011
Last updated: August 13, 2011
Last verified: August 2011
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.

Condition Intervention Phase
Papillary Thyroid Carcinoma Genetic: BRAF V600E POSITIVITY Early Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma

Resource links provided by NLM:

Further study details as provided by Bezmialem Vakif University:

Primary Outcome Measures:
  • BRAF V600E MUTATION [ Time Frame: 2 years ]

Estimated Enrollment: 150
Study Start Date: July 2011
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BRAF V600E POSITIVITY
This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.

Detailed Description:
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with papillary thyroid cancer

Exclusion Criteria:

  • Patients who do not want to be a part of this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01417442

Yeliz Emine Ersoy Recruiting
Istanbul, Turkey, 34308
Contact: Yeliz E Ersoy, DR    +905326102713   
Principal Investigator: Yeliz E Ersoy, M.D.         
Sponsors and Collaborators
Bezmialem Vakif University
  More Information

Responsible Party: Yeliz E. Ersoy, BEZMIALEM VAKIF UNIVERSITY Identifier: NCT01417442     History of Changes
Other Study ID Numbers: 2011/5
Study First Received: July 6, 2011
Last Updated: August 13, 2011

Keywords provided by Bezmialem Vakif University:
papillary thyroid carcinoma
poor prognosis

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms processed this record on September 21, 2017